Ricci Chiara, Saracino Ilaria Maria, Valerii Maria Chiara, Spigarelli Renato, Bellocchio Irene, Spisni Enzo
Gastroenterology Unit, ASST Spedali Civili di Brescia, University of Brescia, Piazza del Mercato 15, 25121 Brescia, Italy.
Microbiology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Nutrients. 2025 Jan 17;17(2):328. doi: 10.3390/nu17020328.
The objective of this study was to evaluate the efficacy of a very-low-absorbable geraniol formulation, administered as a food supplement, in patients with irritable bowel syndrome (IBS) in a real-world setting in Italy.
This open-label study was conducted in Italy on patients diagnosed with IBS and treated for 4 weeks with 240 mg/day of Palmarosa essential oil, absorbed on 960 mg of ginger root powder to obtain a very-low-absorbable geraniol formulation. Baseline characteristics, including demographic and symptoms were recorded using the IBS Severity Scoring System (IBS-SSS). After 28 ± 7 days, the patients were asked to complete the IBS-SSS questionnaire again. The primary objective was to confirm the effects of a very-low-absorbable geraniol formulation on self-reported symptoms of IBS and the quality of life of affected individuals. The secondary objective was to confirm the effect of the treatment on the different IBS subtypes.
A total of 1585 patients were included in the study, with a mean age of 44.8 years and 56.4% women. Following the 4-week supplementation period, significant decreases were observed in the patients' IBS-SSS (-67.9%) and all the primary IBS symptoms, such as abdominal distention (-82.3%), unsatisfaction with bowel habits (-46.2%), and interference with quality of life (QoL) (-64.9%) (all < 0.01). The patients' stool type improved significantly. Treatment was effective in all IBS subtypes.
Treatment with very-low-adsorbable geraniol food supplement was associated with improvements in symptoms and bowel habits in all IBS subtypes in a real-world setting in Italy. These findings support the use of geraniol as an effective option for patients with IBS regardless of the disease subtype.
本研究的目的是在意大利的实际环境中，评估一种作为食品补充剂给药的极低吸收性香叶醇制剂对肠易激综合征（IBS）患者的疗效。
这项开放标签研究在意大利对诊断为IBS的患者进行，患者接受为期4周的治疗，每天服用240毫克玫瑰草精油，该精油吸附于960毫克姜根粉上，以获得极低吸收性香叶醇制剂。使用IBS严重程度评分系统（IBS-SSS）记录包括人口统计学和症状在内的基线特征。在28±7天后，要求患者再次填写IBS-SSS问卷。主要目的是确认极低吸收性香叶醇制剂对IBS自我报告症状和受影响个体生活质量的影响。次要目的是确认治疗对不同IBS亚型的效果。
共有1585名患者纳入研究，平均年龄44.8岁，女性占56.4%。在为期4周的补充期后，患者的IBS-SSS评分显著下降（-67.9%），所有主要的IBS症状，如腹胀（-82.3%）、对排便习惯不满意（-46.2%）以及对生活质量（QoL）的干扰（-64.9%）均显著下降（均P<0.01）。患者的粪便类型有显著改善。治疗对所有IBS亚型均有效。
在意大利的实际环境中，使用极低吸收性香叶醇食品补充剂进行治疗可使所有IBS亚型的症状和排便习惯得到改善。这些发现支持将香叶醇作为IBS患者的有效治疗选择，无论疾病亚型如何。
